The epigenetic rejuvenation business: myths and realities

Epigenetics and rejuvenation: real business or mirage?

The quest for eternal youth has left science fiction behind and moved into the laboratory. Trinc advances in epigenetics, the question circulating in investor circles is direct: can you make money selling cellular rejuvenation before science has proven it works? Judging by the available data, the answer is ambiguous: yes, but only if you have access to capital and patience.

In 2025, a team of researchers managed to revive senescent nerve cells in mice, a milestone that opens the door to anti-aging therapies. Until then, the approach had focused on replacing old cells with stem cells; now it has been shown that reprogramming them is possible. The leap to humans is estimated to be four to six years away, according to industry sources. But it will be neither cheap nor accessible to everyone: mRNA therapies, such as the one proposed to activate the Nanog gene to regenerate telomeres, cost around $30 per injection, a price only the very wealthy can afford at the experimental stage.

Ways into the business

From the sale of dietary supplements —unprocessed animal fat, organic eggs— to young blood transfusions, the anti-aging market is buzzing with proposals. Magnates such as Jeff Bezos and Peter Thiel are known to fund experiments with plasma from young donors, with promising results in patients with cognitive decline. However, the scientific community warns: without controlled clinical trials, any claim of efficacy is speculation.

Skepticism as an investment

Most analyses agree that epigenetic rejuvenation will become a multibillion-dollar sector, but not in the short term. While mice show improvements, the translation to humans is fraught with regulatory and biological uncertainties. Moreover, the cost of the treatments —if they ever arrive— will restrict them to an elite, as is already the case with the most advanced gene therapies. The startling figure: a $30 mRNA injection could, in theory, extend life by 300 years. But that number is a projection based on animals, not people.